Skip to main content
HR 6383 116th Congress House Health Congressional oversight Health care coverage and access Health personnel Health promotion and preventive care Health technology, devices, supplies Medicaid Medical research Minority health Prescription drugs Research administration and funding Sex and reproductive health Women's health

Uterine Fibroid Research and Education Act of 2020

Introduced: March 24, 2020 Introduced by: Clarke, Yvette D. Democratic · New York See on congress.gov
 Everywhere this bill has been 2 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Mar 24, 2020
Referred to the House Committee on Energy and Commerce.
Mar 24, 2020
Introduced in House
 Plain-English summary Congressional Research Service

Uterine Fibroid Research and Education Act of 2020

This bill directs specified components of the Department of Health and Human Services to take certain actions to address uterine fibroids (i.e., muscular tumors that grow in the wall of the uterus and may cause pain, heavy menstrual bleeding, and reproductive issues).

Specifically, the National Institutes of Health (NIH), working through the Office of Research on Women's Health, must undertake research activities on uterine fibroids. In carrying out this research, the office must coordinate with specified components of the NIH and other federal agencies.

In addition, the Centers for Medicare & Medicaid Services must (1) collect data from Medicaid and the Children's Health Insurance Program about treatment and services related to uterine fibroids, and (2) develop a report in coordination with federal partners on federal and state expenditures for these treatments and services.

Additionally, the Centers for Disease Control and Prevention (CDC), the Health Resources Service Administration (HRSA), and the Agency for Healthcare Research and Quality (AHRQ) must disseminate information about uterine fibroids, including the elevated risk for minority women and information regarding available treatments. Specifically, the CDC shall disseminate the information to the public, while HRSA and AHRQ shall disseminate it to health care providers.

What's happening now March 24, 2020

Referred to the House Committee on Energy and Commerce.

 Committees of jurisdiction 1